[20120626]R42564_FDA使用费和药物、生物制品和设备监管:S.3187与H.R.的比较分析5651.pdf
CRS Report for CongressPrepared for Members and Committees of Congress FDA User Fees and the Regulation of Drugs, Biologics, and Devices: Comparative Analysis of S. 3187 and H.R. 5651 -name redacted-, Coordinator Specialist in Drug Safety and Effectiveness -name redacted- Analyst in Health Policy -name redacted- Analyst in Public Health and Epidemiology -name redacted- Specialist in Health Policy -name redacted- Specialist in Biomedical Policy -name redacted- Specialist in Public Health and Epidemiology -name redacted- Specialist in Health Policy June 26, 2012 Congressional Research Service 7-. www.crs.gov R42564
展开阅读全文
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 20120626 R42564_FDA 使用费 药物 生物制品 设备 监管 3187 比较 分析 5651

关于本文
本文标题:[20120626]R42564_FDA使用费和药物、生物制品和设备监管:S.3187与H.R.的比较分析5651.pdf
链接地址:https://www.lianhezuozhan.com/doc/23146.html
链接地址:https://www.lianhezuozhan.com/doc/23146.html